Phase I/II – Other

632 trials 274 recruiting

Filter these 632 trials by condition, country, sponsor and more.

Open in Search →

A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter S… Recruiting

2025-524733-11-00 Unresectable Locally Advanced Pancreatic Cancer 2026-04-22
A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad… Recruiting

2024-520238-31-01 Advanced Lung Cancer 2026-04-20
Sodium selenite in patients with advanced carcinoma: SECAR 1c Recruiting

2025-522798-13-00 Advanced carcinoma 2026-04-17
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (M… Recruiting

2023-506611-17-00 Advanced liver cancers 2026-04-16
MB-CART2019.1 in refractory MS Recruiting

2024-517601-82-00 refractory Multiple Sclerosis 2026-04-01
A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting

2025-521859-23-00 PSMA-positive mCRPC with prior exposure to at least one 2026-03-31
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 Recruiting

2025-521973-16-00 Netherton Syndrome 2026-03-31
Pharmacokinetics, safety, and efficacy of fisetin - A phase I and pilot phase IIa study Recruiting

2023-506284-34-00 Healthy 2026-03-24
Single-center phase I/IIa study with CART cells produced using the anti-CD19 transposon technique (TranspoCART19) for patients with CD19+ ac… Recruiting

2025-522673-11-00 refractory or resistant CD19+ acute lymphoblastic leuke 2026-03-17
A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with… Recruiting

2024-519344-32-00 Non-small Cell Lung Cancer 2026-03-16
Guttmann NeuroRecovery – Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous s… Recruiting

2025-521877-14-00 Traumatic spinal cord injury 2026-03-11
A Study Testing a New Targeted Drug (TUB-040) in combination with Standard Chemotherapy for Women with Ovarian Cancer Recruiting

2025-524691-33-00 High-grade epithelial serous or endometrioid epithelial 2026-03-09
A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigationa… Recruiting

2024-517979-20-00 Advanced Breast Cancer Metastatic Breast Cancer 2026-03-04
An open label, phase I/II study investigating the safety and efficacy of a CD3/CD20 bispecific T-cell engager therapy in patients with activ… Recruiting

2025-522853-21-01 Active, treatment refractory, ANCA-IgG-positive associa 2026-02-27
Inhibiting BCL-2 at the start of HIV treatment to reduce the HIV reservoir in people living with HIV Recruiting

2025-521841-26-00 HIV-1 infection 2026-02-20
Single-centre clinical trial investigating safety and tolerability of repeated administrations of increasing doses of nebulised SS0331 in he… Recruiting

2025-523875-48-00 Chronic airway infections 2026-02-17
A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon… Recruiting

2025-521880-10-00 Metastatic castrate resistant prostate cancer (mCRPC) 2026-02-16
TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat… Recruiting

2025-521873-15-00 Metastatic hormone-sensitive prostate cancer 2026-02-09
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors Recruiting

2025-521828-30-00 Advanced Solid Tumors 2026-01-27
A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment pumit… Recruiting

2025-521768-36-00 Metastatic colorectal cancer 2026-01-27
An open label, phase I/II study investigating the safety and efficacy of the bispecific T-cell engaging antibody cizutamig (BCMAxCD3) in pat… Recruiting

2025-522857-20-00 Severe, treatment refractory primary Sjögren’s disease 2026-01-22
Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting

2025-522090-11-00 Relapsed or Refractory Multiple Myeloma (RRMM) 2026-01-22
A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA Recruiting

2025-521530-28-00 Progressive systemic autoimmune disease resistant to B 2026-01-19
A study of belumosudil in children with chronic graft versus host disease (schoolROCK). Recruiting

2024-511508-18-00 Chronic graft versus host disease. 2026-01-05